Artificial Intelligence and the Future of the Russian IP Office - International Trademark Association inta.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from inta.org Daily Mail and Mail on Sunday newspapers.
The Eurasian Patent Office (EAPO) has announced that it will accept Eurasian design patent applications from 1 June 2021.
On 9 September 2019 the Protocol on the Protection of Industrial Designs to the Eurasian Patent Convention was signed in Nur-Sultan, Kazakhstan. According to the protocol, rights holders will be able to obtain legal protection for their industrial designs in all member states through a single Eurasian patent.
A Eurasian design patent will have legal effect within a member state s territory where the corresponding Eurasian design application has been filed after the protocol has taken effect in that state.
As of 15 April 2021 the protocol had taken effect in five out of the eight member states – namely:
[author: Vladislav Ugryumov ]
On March 1, 2021, the Eurasian Patent Office (EAPO) launched the EAPO Pharmaceutical Register (the Register ). The Register lists Eurasian patents that relate to the active pharmaceutical ingredients of the drugs according to their International Non-proprietary Names (INN). The Register resides on the EAPO web site. It is currently available in Russian and the English version is expected soon.
The Register does not implement a patent linkage system that would prevent a generic drug from getting Marketing Authorization before expiry of the originator s patents. The Register was launched to facilitate locating Eurasian pharmaceutical patents that have issued, their status in each of the EAPO Contracting States, patent term extensions if granted and registered licenses. The Register covers compound patents including small and large molecules, as well as formulation patents including pharmaceutical composition and combination patents, second medical use p
Search jobs 10-Feb-2021 Thrombolytic Science Reinforces Its IP Portfolio with Patents in Europe, the Commonwealth of Independent States and Japan
Thrombolytic Science Reinforces Its IP Portfolio with Patents in Europe, the Commonwealth of Independent States and Japan
New Patents to Support Global Partnering of Novel Bio-inspired Clot-dissolving Therapy
CAMBRIDGE, MA, February 10, 2021 / B3C newswire / Thrombolytic Science, LLC (TSI) today announced the granting of three new patents during the last 12 months. The invention relates to methods and compositions for safe and effective thrombolysis for ischemic stroke and heart attacks.
The two patents are part of a family of applications based on the international application No. PCT/US2015/058878. The European Patent Office granted Patent Number EP3215221 on February 26, 2020 and has been nationalized in 11 European countries. The Eurasian Patent Office granted Patent Number 03
(0)
DGAP-News: Thrombolytic Science, LLC / Key word(s): Patent/Research Update
Thrombolytic Science, LLC: Thrombolytic Science Reinforces Its IP Portfolio with Patents in Europe, the Commonwealth of Independent States and Japan
10.02.2021 / 12:00
Thrombolytic Science Reinforces Its IP Portfolio with Patents in Europe,
the Commonwealth of Independent States and Japan
New Patents to Support Global Partnering of Novel Bio-inspired Clot-dissolving Therapy
CAMBRIDGE, MA, February 10, 2021 Thrombolytic Science, LLC (TSI) today announced the granting of three new patents during the last 12 months. The invention relates to methods and compositions for safe and effective thrombolysis for ischemic stroke and heart attacks.
The two patents are part of a family of applications based on the international application No. PCT/US2015/058878. The European Patent Office granted Patent Number EP3215221 on February 26, 2020 and has been nationalized in 11 European countries. The Eurasian